Pharmaceutical industry: latest news

Pharmaceutical industry features

Pharmaceutical industry news from aidsmap

More news

Pharmaceutical industry news selected from other sources

  • As EU Approval Moves Closer Are Governments Prepared For PrEP?

    On Friday the EU's Committee for Medicinal Products for Human Use (CHMP) announced its positive opinion on Gilead’s HIV pre-exposure prophylaxis product Truvada PrEP. But with many European governments trying to control healthcare costs, the biggest issue facing Truvada PrEP might not be approval but rather reimbursement.

    27 July 2016 | Seeking Alpha
  • South Africa: Produce HIV Drugs Locally, Says Science Minister

    Durban -South Africa should advocate for the creation of local HIV drug manufacturing companies and stop depending on foreign pharmaceutical multinationals for these drugs, says Science and Technology Minister Naledi Pandor.

    22 July 2016 | AllAfrica
  • HIV Drug Pricing Protest Interrupts PrEP Session at AIDS 2016

    Protesters against the high cost of antiretroviral drugs joined forces and marched together today, interrupting a research presentation today at the 21st International AIDS Conference (AIDS 2016).

    21 July 2016 | BETA blog
  • Challenges Loom for Point-of-Care Diagnostics

    POC is likely to grow in emerging markets, where limited resources and local conditions make traditional lab-based testing less practical.

    13 July 2016 | Genetic Engineering & Biotechnology News
  • Gilead defeats AIDS activists who claimed the company manipulated patents

    Gilead Sciences won a victory last week when a federal court judge tossed a lawsuit in which an AIDS activist group accused the drug maker of manipulating the patent system in order to thwart competition for its HIV medicines. At issue was tenofovir, or TDF, which Gilead is replacing with a modified version known as TAF.

    13 July 2016 | STAT
  • The Medicines Patent Pool Signs New Round of Generic Manufacturing Licences for HIV and Hepatitis C Treatments

    The Medicines Patent Pool (MPP) announced new generic manufacturing licences today for four antiretrovirals and hepatitis C direct-acting antiviral daclatasvir. The organisation signed licences with Aurobindo, Desano, Emcure, Hetero Labs, Laurus Labs, Lupin and new partner Zydus Cadila for a total of nine new sub-licensing agreements to produce generic versions of key World Health Organization-priority HIV and hepatitis C treatments.

    11 July 2016 | Medicines Patent Pool
  • Gilead’s new price hikes on HIV drugs anger AIDS activists

    As part of a strategy to switch patients to newer HIV treatments, Gilead Sciences late last week raised prices on a pair of older HIV medications that face patent expiration. This sort of maneuver is often found in the pharmaceutical playbook, but is triggering still more criticism by AIDS activists of its overall pricing strategies.

    06 July 2016 | STAT
  • How To Avoid Black Market HIV Drugs

    HIV drugs are big business — and not just to the companies that manufacture them and the pharmacies that sell them. They are also a growing portion of the drugs flooding the black market, generally stolen or counterfeit medications.

    04 July 2016 | HIV Plus
  • Brexit spells upheaval for EU and UK drug regulation

    Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have to relocate. Britain's biggest drugmaker, GlaxoSmithKline, said the exit vote "creates uncertainty and potentially complexity for us in the future".

    30 June 2016 | Reuters
  • Gilead’s single tablet regimen Odefsey receives European marketing approval for HIV treatment

    The European Commission has granted marketing authorization for Gilead Sciences' once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection in certain patients.

    27 June 2016 | PharmaBiz
More news


Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close